Clinical Trials on Hereditary Leiomyomatosis and Renal Cell Cancer

Total 10890 results

National Cancer Institute (NCI)

Terminated

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
National Cancer Institute (NCI)

Completed

Tandutinib in Treating Patients Who Have Undergone Surgery for Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
Roswell Park Cancer Institute
AVEO Pharmaceuticals, Inc.

Withdrawn

Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer

Stage III Renal Cell Cancer | Stage II Renal Cell Cancer
University of California, Davis
Pharmacyclics LLC.

Completed

Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer

Metastatic Renal Cell Cancer | Stage IV Renal Cell Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)

Metastatic Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Unresectable Renal Cell Carcinoma

United States
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

Unresectable Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma | Metastatic Papillary Renal Cell Carcinoma | Locally Advanced Papillary Renal Cell Carcinoma

United States, Canada
University of Chicago
National Cancer Institute (NCI)

Terminated

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer

Metastatic Renal Cell Cancer | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
University of Michigan Rogel Cancer Center

Completed

Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer

Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma

United States
University of Washington
Merck Sharp & Dohme LLC; Prometheus Laboratories

Terminated

Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer

Metastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Advanced Clear Cell Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
Pfizer

Completed

A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.

Kidney Cancer | Kidney Neoplasms | Renal Cell Carcinoma | Renal Cancer | Renal Cell Cancer | Cancer of the Kidney | Cancer of Kidney

Finland
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer

Fatigue | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer

Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
Centre Hospitalier Universitaire de Saint Etienne

Terminated

Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer (CA9CRM)

Metastatic Renal Cell Carcinoma | Metastatic Kidney Cancer

France
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Recruiting

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

CBM588, Nivolumab, and Ipilimumab in Treating Patients With Stage IV or Advanced Kidney Cancer

Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Advanced Renal Cell Carcinoma | Unresectable Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Advanced Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Advanced Sarcomatoid Renal Cell Carcinoma

United States
Associació per a la Recerca Oncologica, Spain
Novartis; Pivotal S.L.

Terminated

Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer (SUNRISES)

Metastatic Renal Cell Carcinoma

Spain, Greece, France
National Cancer Institute (NCI)

Terminated

Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7

United States
Central European Society for Anticancer Drug Research

Completed

Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib

Non-clear Cell Renal Cell Cancer

Germany
Queen Mary University of London
Novartis

Completed

Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer (DEVELOP)

Metastatic Clear Cell Renal Cancer

United Kingdom
National Cancer Institute (NCI)

Terminated

SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment

Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
NiKang Therapeutics, Inc.
Pfizer

Recruiting

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

Neoplasms | Kidney Cancer | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Neoplasms by Site | Kidney Diseases | Urologic Diseases | Adenocarcinoma | Carcinoma | Neoplasms, Glandular and Epithelial | Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Recurrent... and other conditions

United States
Roswell Park Cancer Institute

Completed

Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery

Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer

Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
National Cancer Institute (NCI)

Completed

Carboxyamidotriazole in Treating Patients With Metastatic Kidney Cancer

Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Recruiting

Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

Kidney Cancer | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8

United States
Roswell Park Cancer Institute
Pfizer

Completed

Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery

Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Clear Cell Sarcoma of the Kidney

United States, Netherlands
Steba Biotech S.A.
PrimeVigilance; ICON plc

Recruiting

ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study (UCM301)

Transitional Cell Cancer of Renal Pelvis and Ureter

United States, Israel, Spain, Italy, France, Germany, Austria
National Cancer Institute (NCI)

Completed

Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Type 1 Papillary Renal Cell Carcinoma | Type 2 Papillary Renal Cell Carcinoma

United States, Taiwan, Australia
University of California, San Francisco
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab With or Without Axitinib for Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery

Clear Cell Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Recurrent Clear Cell Renal Cell Carcinoma

United States
Lawson Health Research Institute
Hamilton Health Sciences Corporation; London Health Sciences Centre

Completed

Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers in Renal Cancer

Clear Cell Renal Cancer | Circulating Tumor Cells | Predictive Biomarkers | Prognostic Biomarkers | Circulating Endothelial Cells

Canada
National Cancer Institute (NCI)

Completed

A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer

Kidney Cancer

United States
National Cancer Institute (NCI)
Canadian Cancer Trials Group

Active, not recruiting

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PROSPER)

Metastatic Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Unclassified Renal Cell Carcinoma | Stage II Renal Cell Cancer AJCC v7

United States, Canada, Israel
Debiopharm International SA

Recruiting

A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC) | Clear Cell Renal Cell Cancer (ccRCC)

France, Australia
National Cancer Institute (NCI)

Active, not recruiting

A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)

Metastatic Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Unresectable Renal Cell Carcinoma | TFE3-Rearranged Renal Cell Carcinoma

United States, Puerto Rico
Mayo Clinic
National Cancer Institute (NCI)

Active, not recruiting

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer

Metastatic Renal Cell Cancer | Recurrent Renal Cell Carcinoma | Sarcomatoid Renal Cell Carcinoma | Stage IV Renal Cell Cancer | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Kidney Medullary Carcinoma | Kidney Oncocytoma | Carcinoma of the Collecting Ducts of Bellini

United States
University of Southern California
National Cancer Institute (NCI)

Active, not recruiting

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Cancer | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Clinical Study of 6MW3211 in Patients With Renal Cancer

Advanced Clear Cell Renal Cell Carcinoma
National Cancer Institute (NCI)

Active, not recruiting

Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma | Locally Advanced Malignant Solid Neoplasm | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Locally Advanced Clear Cell Renal Cell Carcinoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Nivolumab and Ipilimumab With and Without Camu Camu for the Treatment of Patients With Metastatic Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Sarcomatoid Renal Cell Carcinoma

United States
National Cancer Institute (NCI)

Completed

A Study of RO4929097 in Patients With Advanced Renal Cell Carcinoma That Have Failed Vascular Endothelial Growth Factor (VEGF)/Vascular Endothelial Growth Factor Receptor (VEGFR) Therapy

Clear Cell Renal Cell Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer

Canada
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer

Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
Institut Cancerologie de l'Ouest
Fondation ARC; University of Angers, GRANEM

Unknown

Safety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs (TOPTACOS)

Stage III Renal Cell Cancer | Metastatic Renal Cancer

France
University of Southern California
National Cancer Institute (NCI)

Terminated

sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer

Stage III Renal Cell Cancer | Recurrent Bladder Carcinoma | Stage I Prostate Cancer | Stage III Prostate Cancer | Infiltrating Bladder Urothelial Carcinoma | Stage II Bladder Urothelial Carcinoma | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage I Renal Cell Cancer | Stage II Renal Cell Cancer

United States
Herlev and Gentofte Hospital

Not yet recruiting

Patient Reported Outcomes by Patients With Metastatic Renal Cell Carcinoma (PRORECECA)

Kidney Cancer | Urologic Neoplasms | Metastatic Renal Cell Carcinoma | Urologic Cancer | Advanced Renal Cell Carcinoma | Kidney Neoplasm

Denmark

Clinical Trials on Hereditary Leiomyomatosis and Renal Cell Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations